Compare CKX & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CKX | LPCN |
|---|---|---|
| Founded | 1930 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.4M | 18.7M |
| IPO Year | 1996 | 2011 |
| Metric | CKX | LPCN |
|---|---|---|
| Price | $15.86 | $1.69 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | ★ 476.1K | 212.9K |
| Earning Date | 11-24-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1125.00 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | $838,543.00 | ★ $1,976,677.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.02 |
| P/E Ratio | $178.06 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.66 | $1.36 |
| 52 Week High | $24.74 | $12.37 |
| Indicator | CKX | LPCN |
|---|---|---|
| Relative Strength Index (RSI) | 70.02 | 52.99 |
| Support Level | $10.04 | $1.36 |
| Resistance Level | N/A | $2.30 |
| Average True Range (ATR) | 1.44 | 0.11 |
| MACD | 0.62 | 0.04 |
| Stochastic Oscillator | 37.93 | 84.62 |
CKX Lands Inc is a Louisiana corporation organized to receive non-producing mineral royalties spun off by a southwest Louisiana bank. It operates in three segments: Oil and Gas, Surface, and Timber. The company owns land and mineral interests and collects income through its ownership of oil and gas royalties, surface leases for farming, the right of way, and other uses, and timber sales. The company's oil and gas royalties are paid by the operators who own the wells, and timber income is paid by the highest bidder for the timber. It has small royalty interests in approximately 20 different producing oil and gas fields. Maximum revenue for the company is generated from the Timber segment.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.